baber/WOPTO huggingface dataset:
Patent NZ-575936-A (NZ)
Title: Packaging system for pharmaceutical compositions and kit for intravenous administration
Inventor: MAGRI PAOLO
IPC: A61J1/20
Filed: 2007-09-28
Abstract: A method of transferring a pharmaceutical composition to perform a parenteral administration, said method comprising the steps of: providing a container holding a fluid for parenteral infusion, said container being made of a collapsible material and containing up to 500 ml of a saline solution; providing a connector having at least two spikes, one of said at least two spikes penetrating inside a rubber cap of said container; providing a bottle in the form of a dosage unit having a capacity of 6ml to 9ml and containing the pharmaceutical composition which comprises 5mg of tacrolimus dissolved in 1ml of solvent composed of 200 mg of polyoxyethylenated hydrogenated castor oil (HCO-60) and ethanol q.s. to 1 ml, said bottle adapted for connection to the connector in which at least one other of the at least two spikes perforates a rubber cap of the bottle after removal of a metal cap usually present on top of the rubber cap of the bottle wherein such connection is performed with the bottle being upside down; thereafter applying light pressure to the container, whereupon the fluid for infusion passes through the at least two spikes of the connector in order to wash out the bottle which has an empty volume of between 5ml and 8ml in order to substantially flush out or transfer the pharmaceutical composition from the bottle to the container.
Patent NZ-582049-A (NZ)
Title: Transdermal delivery devices assuring an improved release of an active principle through a biological interface
Inventor: ISHIKAWA CHIZUKO
IPC: A61K9/06
Filed: 2008-05-16
Abstract: Discloses is a passive transdermal delivery device comprising: a backing substrate; and an active agent layer, wherein the active agent layer is substantially anhydrous and oil-free and includes as thickening agent a cellulose derivative and an ionizable active agent, wherein the ionizable active agent is electrically neutral in the active agent layer and dissociates into an ionized active agent upon contacting an aqueous medium and is selected from the group comprising: a beta-adrenergic agonist, Procaterol HCI, a salt of a carboxylic acid-containing active agent, and L-ascorbic acid or a derivative thereof. Also disclosed is a topical formulation comprising the composition and a use of the composition for the manufacture of a medicament for treating an obstructive respiratory ailment.
Patent NZ-583592-A (NZ)
Title: Synergistic fungicidal active substance combinations of N-(3',4'-dichloro-5-fluoro-1,1'-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and a conazole
Inventor: DAHMEN PETER
IPC: B62D33/02
Filed: 2004-09-28
Abstract: Disclosed are synergistic fungicidal active compound combinations comprising the carboxamide (1-1) N-(3',4'-dichloro-5-fluoro-1,1'-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and at least one active compound selected from the following triazoles: propiconazole, epoxiconazole, tebuconazole, bitertanol and prothioconazole. Further disclosed is a method for controlling unwanted phytopathogenic fungi, by applying to the unwanted phytopathogenic fungi and/or their habitat a combination as described above.
Patent NZ-587007-A (NZ)
Title: Steering engagement catheter devices, systems and methods
Inventor: KASSAB GHASSAN S
IPC: A61M25/01
Filed: 2008-08-13
Abstract: 587007 Steering engagement catheter devices, systems, and methods of using the same for accessing tissue, including the internal and external tissues of the heart, are disclosed. In at least one embodiment, a steering engagement catheter is provided, comprising an elongated tube having a proximal end, a distal end, and a first wall positioned circumferentially along a length of the elongated tube, the elongated tube configured such that a delivery catheter is capable of at least partial insertion into the elongated tube, at least one steering wire having a proximal end and a distal end, the distal end of the steering wire coupled to the first wall of the elongated tube at or near the distal end of the elongated tube, and a controller operably coupled to the at least one steering wire at or near the proximal end of the at least one steering wire. A flared skirt is provided at the distal end of the elongated tube and is operable to form a reversible seal with a surface of a tissue on application of vacuum via a vacuum port.
Patent NZ-589010-A (NZ)
Title: Pyrrole antifungal agents
Inventor: SIBLEY GRAHAM EDWARD MORRIS
IPC: A01N43/36
Filed: 2009-04-23
Abstract: Disclosed herein is a pyrrole derivative of formula (I), wherein the substituents are as defined within the specification, processes for its preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as agricultural fungicides. Specifically preferred examples include: · 2-(1,5-Dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{ 4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-oxo-acetamide, · N-{ 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-oxo-2-(1-phenyl-1H-pyrrol-2-yl)-acetamide, · N-{ 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-(5-methyl-1-phenyl-1Hpyrrol-2-yl)-2-oxo-acetamide, · N-{ 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-(5-methyl-1H-pyrrol-2-yl)-2-oxo-acetamide, · 2-[3-(4-Chloro-phenyl)-1-(2-methoxy-ethyl)-1H-pyrrol-2-yl]-N-{ 4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-oxo-acetamide, · 2-[1-(2-Methoxy-ethyl)-5-methyl-3-phenyl-1H-pyrrol-2-yl]-2-oxo-N-phenyl-1-acetamide, · (2-{ 4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenylaminooxalyl} -pyrrol-1-yl)-acetic acid methyl ester,
Patent NZ-593227-A (NZ)
Title: Gene expression markers (MYBL2) for colorectal cancer prognosis
Inventor: COWENS WAYNE
IPC: C12Q1/68
Filed: 2007-01-11
Abstract: Disclosed is a method of predicting clinical outcome for a human subject following surgical resection of colorectal cancer, the method comprising: a.) Determining a normalised level of RNA transcript of MYBL2, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject; and b.) Predicting the likelihood of a positive clinical outcome for said human subject by comparing said normalised level to gene expression data obtained from colorectal cancer reference samples derived from patients with colorectal cancer, wherein increased normalised level of an RNA transcript of MYBL2, or an expression product thereof, is positively correlated with an increased likelihood of a positive clinical outcome.
Patent NZ-594452-A (NZ)
Title: Anti-mst1r antibodies and uses thereof
Inventor: KAWAIDA REIMI
IPC: A61K39/00
Filed: 2010-02-10
Abstract: Provided is an isolated human or humanized antibody or functional fragment thereof comprising an antigen-binding region that is specific for a partial peptide of MST1R, having an amino acid sequence, wherein the antigen-binding region comprises specified sequences of the three light chain CDRs and the three heavy chain CDRs. Further provided are corresponding encoding DNA sequences. The antibody can be used to treat tumours and neoplasms.
Patent NZ-596868-A (NZ)
Title: Antagonism of human formyl peptide receptor for treatment of disease
Inventor: BENSON JOHN D
IPC: A61K31/549
Filed: 2010-06-02
Abstract: 596868 Disclosed herein are modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases, such as a pulmonary or inflammatory disease. Examples of the modulators disclosed herein are a cyclosporine H derivative of formula I, wherein the variables are defined in the specification, cyclosporine H or dihydro cyclosporine H.
Patent NZ-598039-A (NZ)
Title: Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
Inventor: WAUGH JACOB M
IPC: A61K38/00
Filed: 2007-12-12
Abstract: 598039 Disclosed is a method for stabilizing botulinum toxin, said method comprising combining a botulinum toxin complex or a reduced botulinum toxin complex comprising botulinum toxin with a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO.1 (Arg Lys Lys Arg Arg Gln Arg Arg Arg (RKKRRQRRR)), or with a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO.2 (Arg Arg Arg Gln Arg Arg Lys Lys Arg (RRRQRRKKR)); wherein the polypeptide is present in an amount effective to stabilize the botulinum toxin. Further disclosed is a composition, comprising: a botulinum toxin complex or a reduced botulinum toxin complex comprising botulinum toxin; and a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO.2; wherein the polypeptide is present in an amount effective to stabilize the botulinum toxin composition.
Patent NZ-601038-A (NZ)
Title: Heat-shrinkable multi-layer film for deep-draw forming, and process for production thereof
Inventor: UEYAMA TAKAHISA
IPC: B32B27/32
Filed: 2010-12-17
Abstract: 601038 Disclosed is a heat-shrinkable multilayer film adapted for deep draw forming, comprising: a surface layer (a) comprising a thermoplastic resin (such as PET), an intermediate layer (b) comprising a polyamide resin, and a surface layer (c) comprising a sealable resin (such as a polyolefin), wherein, (A) the intermediate layer (b) comprises a mixture of an aliphatic polyamide having a melting point of at least 180oC (such as nylon 6 or nylon 6-66), and an amorphous aromatic polyamide comprising a polycondensation product of an aliphatic diamine with isophthalic acid and terephthalic acid as main acid components (such as nylon 6I-6T), including 25-45 wt.% of the amorphous aromatic polyamide, and has a thickness exceeding 25% and at most 50 % of a total thickness of whole layers , and the multilayer film exhibits: (B) tensile stresses at an elongation of 100% as measured in a tensile test at 100oC, including 3-22 MPa in at least one of a longitudinal direction (MD) and a transverse direction (TD) and an average of MD and TD values of 3-20 MPa, and (C) a shrinkage in hot water at 90oC of 3 to 20% in each of MD and TD. Further disclosed is a method for preparing the above film which includes a step of vertically pulling a tubular product while introducing a fluid into the tubular product to stretch the tubular product 2.1 - 2.4 times in the vertical direction and 2.1 - 2.6 times in the circumferential direction to form a biaxially stretched tubular film, folding the tubular film, again introducing a fluid into the folded tubular film to form a tubular film, heat-treating the tubular film from its surface layer (a) side with steam or warm water to provide a relaxation ratio of 20 - 35 % in each of the vertical direction and the circumferential direction, and cooling the heat-treated tubular film to obtain a stretch-oriented multilayer film.
Patent NZ-608309-A (NZ)
Title: Mineral-releasing compost and method of using the same for soil remediation
Inventor: HOXSEY JANE A
IPC: C07C59/01
Filed: 2011-08-16
Abstract: This disclosure relates to a mineral-releasing compost prepared by combining a prebiotic material, cellulosic plant material, a probiotic material, Lactobacillus, and one or more mineral gluconate salts to form a composting mixture. The composting conditions are controlled to allow for the composting mixture to decompose and fully stabilize and mature, wherein the compost then includes one or more minerals as digested products of the respective mineral gluconate salts. The minerals can include copper, iron (both ferric and ferrous forms) magnesium, zinc, cobalt, calcium and potassium, wherein the preferred embodiment contains ferrous iron. The mineral-releasing compost is particularly suitable for remediation of soil contaminated with heavy metals (see Fig. 1) and for amendment of soil deficient of certain minerals.
Patent NZ-608431-A (NZ)
Title: Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
Inventor: WONG ROBERT L
IPC: G01N33/68
Filed: 2006-10-31
Abstract: Disclosed is a method for determining the efficacy of adalimumab for the treatment of ankylosing spondylitis (AS) in a subject having AS, said method comprising determining a post-treatment level of type II collagen C-telopeptide (CTX-II) in a sample(s) obtained from the subject having AS, wherein a decrease in the level of CTX-II of at least 9% relative to a known standard level of CTX-II based on a subject(s) having AS indicates that adalimumab is efficacious for the treatment of AS in the subject.
Patent NZ-609860-A (NZ)
Title: An inserter for an intrauterine system
Inventor: JUTILA ILKKA
IPC: A61F6/14
Filed: 2011-10-26
Abstract: An inserter for an intrauterine system (IUS) or intrauterine device (IUD) is disclosed. The inserter comprises a handle with a longitudinal opening extending parallel to the longitudinal axis of the inserter. The inserter further comprises a movable plunger (2), an insertion tube (6) arranged around the plunger, a movable slider (5) arranged in the opening and a locking means for locking the intrauterine system in relation to the plunger (2) during insertion via a removal string. The inserter includes rotating movement means (19) connected to the plunger (2), slider (5) and tube (6). The movement means (19) is arranged so that movement of the slider (5) generates simultaneous movement of the plunger (2) and insertion tube (6) in opposite directions.
Patent NZ-615260-A (NZ)
Title: Step-climbing attachment for a wheeled chair
Inventor: BEHRENS MICHAEL
IPC: B62B9/02
Filed: 2012-02-07
Abstract: A step-climbing attachment for a wheeled chair, the attachment including a wheel-mounting chassis for mounting wheels, a first and a second wheel each mounted on the wheel-mounting chassis for rotation about their axes, the first and second wheels are each adapted to move relative to the other, the relative movement in use being between a ground engaging position and a step-engaging position so that in use at least one of the first or second wheels engages a step, and respective link arms 128 connected to the chassis so as to mount the first wheel and the second wheel to the chassis and allow each wheel to swing from the ground engaging position to the step-engaging position. At least one of the wheels has a hub 135 and a motor 190 and gearbox mounted within the hub. The motor and gearbox are connected to the respective link arms 128 so as to pivot the other of the first or second wheels into a step engaging position.
Patent NZ-617344-A (NZ)
Title: Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with high temperature short time heat treatment apparatus
Inventor: WONG BING LOU
IPC: C07K14/805
Filed: 2012-04-23
Abstract: Disclosed is a method for the preparation of a highly purified and heat stable oxygen carrier containing pharmaceutical composition, the oxygen carrier-containing pharmaceutical composition including haemoglobin, the haemoglobin including cross-linked polymeric haemoglobin, the method comprising: (a) providing whole blood including at least red blood cells and plasma; (b) separating the red blood cells from the plasma in the whole blood; (c) filtering the red blood cells that were separated from the plasma to obtain a filtered red blood cell fraction; (d) lysing the red blood cells to create a solution comprising a lysate of disrupted red blood cells; (e) extracting a first haemoglobin solution from the lysate; (f) performing one or more purification processes to produce a purified haemoglobin solution; (g) cross-linking haemoglobin tetramers to create a solution including cross-linked polymeric haemoglobin, the polymeric haemoglobin including two or more cross-linked haemoglobin tetramers; (h) heat treating the solution including the cross-linked polymeric haemoglobin in a deoxygenated environment at a temperature greater than 85°C and less than or equal to approximately 95°C for a period of less than approximately 40 minutes to denature and precipitate any residual non-cross-linked tetrameric haemoglobin, any dimeric haemoglobin, and any other impurities such to form a heat stable solution including a cross-linked polymeric haemoglobin; (i) cooling the heat-treated solution to a temperature approximately less than or equal to 25 °C in approximately two minutes or less to prevent formation of met-haemoglobin; (j) removing precipitate by a centrifugation or a filtration apparatus to form a solution of purified, heat stable haemoglobin including cross-linked polymeric haemoglobin having an undetectable concentration of dimer.
Patent NZ-617351-A (NZ)
Title: Amorphous solid salts of cobicistat (gs-9350)
Inventor: KOZIARA JOANNA M
IPC: C07D277/28
Filed: 2012-04-30
Abstract: Disclosed is the amorphous solid of a compound of formula (I), optionally in the form of its pharmaceutically acceptable salts. Further disclosed are methods for preparing the above compound, pharmaceutical compositions which comprise the above compound with additional therapeutic agents, the use of the above compound for the preparation of a medicament for administration to a patient to improve the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, and for the treatment of HIV infection. The chemical name of the amorphous solid of a compound of formula (I) is: ((thiazol-5-yl)methyl) (2R,5R)-5-(((S)-(3-((isopropylthiazol-4-yl)methyl)-3-methylureido)-2-(morpholinoethyl)ethyl)amido)-1,6-diphenylhexan-2-ylcarbamate
Patent NZ-618025-A (NZ)
Title: Antibody polypeptides that antagonize cd40
Inventor: SURI ANISH
IPC: C07K16/28
Filed: 2012-04-20
Abstract: Disclosed is an antibody polypeptide comprising a first variable domain, wherein the antibody polypeptide specifically binds an epitope of human CD40, wherein the antibody polypeptide competes with the binding of domain antibody (dAb) BMS3h-56-269 (SEQ ID NO: 417) to CD40, wherein CD40 comprises the amino acid sequence of SEQ ID NO: 1, and wherein the epitope comprises at least one CD40 amino acid residue selected from the group consisting of Trp109, Leu121, His122, Ser124, Ser156, Ala157, Phe158, Glu159, and His162, wherein the antibody polypeptide is a domain antibody, and wherein the binding of the antibody polypeptide to CD40 antagonizes CD40 activity, wherein the sequence is as defined in the specification.
Patent NZ-620075-A (NZ)
Title: A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders
Inventor: KARL JOHANN
IPC: G01N33/68
Filed: 2012-08-21
Abstract: An in vitro method of predicting a response for patients, having neurodevelopmental, neurological or neuropsychiatric disorders, if treated with a compound, targeting the glutamatergic pathway, comprises the steps i) determining the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof in a sample of a patient and ii) comparing the protein concentration determined in step i) to a value representative of the protein concentration of one, two three, four, five or six members of complement factor H family in patients, having neurodevelopmental, neurological or neuropsychiatric disorders. A higher protein concentration of one, two three, four five or six members from complement factor H family in the sample of the patient having neurodevelopmental, neurological or neuropsychiatric disorders is indicative for a patient who will derive clinical benefit from this treatment. The method further comprises iii) selecting this treatment for patients having neurodevelopmental, neurological or neuropsychiatric disorders. Also disclosed is an in vitro method of predicting a response for patients, having neurodevelopmental, neurological or neuropsychiatric disorders, if treated with a compound targeting the glutamatergic pathway, wherein the protein concentration of individual members of the complement factor H family or a mixture or a combination thereof are determined by measuring genetic variants of complement factor H family members. Complement factor H family members are useful as predictive markers for patients who are treated with compounds targeting the glutamatergic pathway or for patients who are treated with a glycine reuptake inhibitor.
Patent NZ-622262-A (NZ)
Title: Easy opening packaging article
Inventor: ODABASHIAN ROBERT A
IPC: B65D75/58
Filed: 2012-09-25
Abstract: An easy opening packaging article, such as an end-seal bag or the like, having a tear initiator (50) and one or more grip assisters (100). According to various embodiments, the tear initiator and grip assisters are configured to assist a user in opening the packaging article. In particular, the grip assisters are configured to reduce the likelihood that a loose piece of plastic is generated during the opening process, and to reduce the likelihood that undesired tears in the packaging article are generated during the opening process.
Patent NZ-629953-A (NZ)
Title: Method and system of generating audit procedures and forms
Inventor: KERSHNER MARRIETTE L
IPC: G06Q50/18
Filed: 2008-10-24
Abstract: A system and a method for assessing risks associated with a financial audit of recorded financial items are disclosed. The system comprises a computer having an associated memory, display, and input device and adapted to execute code; a graphical user interface adapted to operate on the computer and adapted to present a plurality of financial audit procedures for verifying recorded financial items and a set of risk levels associated with the plurality of financial audit procedures and adapted to receive a set of responses by the input device; a response code set adapted to be executed on the computer and adapted to process the set of responses; an audit code set adapted to be executed by the computer and adapted to automatically generate a financial audit approach set for verifying recorded financial items based at least in part on the set of responses, the financial audit approach set including a suggested financial audit approach and an alternative financial audit approach; and a code set adapted to present for selection at least one financial audit approach from the financial audit approach set.
Patent NZ-705624-A (NZ)
Title: Compositions and methods for treating ocular edema, neovascularization and related diseases
Inventor: PETERS KEVIN G
IPC: A61P27/00
Filed: 2011-10-05
Abstract: Disclosed are methods for the treatment of diseases or conditions of the eye with HPTP-beta inhibitors, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. Also disclosed are compositions comprising HPTP-beta inhibitors suitable for treating eye diseases and conditions.
Patent NZ-715475-A (NZ)
Title: Ampoule for a medical liquid, and method for producing an ampoule
Inventor: BRANDENBURGER TORSTEN
IPC: A61J1/14
Filed: 2014-07-15
Abstract: The invention relates to an ampoule (1) for a medical liquid, comprising an ampoule body (10) for receiving a medical liquid and a connection part (11) for connecting a removal device to the ampoule (1). The ampoule body (10) is produced as a plastic injection-molded part by means of a plastic injection molding process. In this manner an ampoule is provided which allows a simple and inexpensive production of them ampoule and can ensure a sterile storage of medical liquids.